UniversitÃ¤tsklinik Innsbruck Trials

UniversitÃ¤tsklinik Innsbruck	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Marth, Christian

MATAO, NCT04111978 / 2019-002264-27: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer

Recruiting

540

Europe

Letrozole 2.5mg, Femara, Placebo

Swiss GO Trial Group, AGO Study Group, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Reliable Cancer Therapies, Krebsliga Schweiz, Stiftung Guido Feger, Hoffmann-La Roche, Helsana AG, Novartis Pharmaceuticals, Anticancer Fund, Belgium

Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC), Low-grade Serous Ovarian Carcinoma (LGSOC), Ovarian Endometrioid Carcinoma

10/25

10/30

ENGOT en-21, NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting

2/3

268

Europe, Canada, US, RoW

Navtemadlin, KRT-232, Navtemadlin Placebo

Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation

Endometrial Cancer

08/25

07/27

N-Plus, NCT05460000: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Recruiting

640

Europe

3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy

North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma

05/27

05/32

SHAPE, NCT01658930: Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

Completed

N/A

700

Europe, Canada, RoW

Radical Hysterectomy + pelvic lymph node dissection, Simple hysterectomy + pelvic lymph node dissection

Canadian Cancer Trials Group, Gynecologic Cancer Intergroup (GCIG), Canadian Institutes of Health Research (CIHR), Korean Gynecologic Oncology Group, Dutch Gynecologic Oncology Group, Cancer Trials Ireland, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Belgium Gynecologic Oncology Group, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Institute of Cancer Research, United Kingdom, Shanghai Cancer Centre Deptartment of Gynecologic Oncology Fudan University, Hertzen Moscow Scientific Research Institute of Oncology, Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom Germany, Institut Claudius Regaud - Institute Universitaire du Cancer de Toulouse - Oncopole

Cervical Cancer

03/23

11/24

NCT04369352: Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria

Recruiting

N/A

150

Europe

Medical University Innsbruck

Recurrent Ovarian Carcinoma

12/24

08/25

Wolf, Dominik

LUSPLUS, NCT05181592 / 2020-004899-18: Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

Recruiting

Europe

Luspatercept, Reblozyl

GWT-TUD GmbH, Celgene

Myelodysplastic Syndromes

12/24

06/25

CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting

897

Europe, RoW

Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro

German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche

Chronic Lymphoid Leukemia

09/27

DASTOP2, NCT03573596: Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

Recruiting

134

Europe

Dasatinib

Amsterdam UMC, location VUmc, Uppsala University Hospital, Skane University Hospital, Helsinki University Central Hospital, Odense University Hospital, Henri Mondor University Hospital, St. Olavs Hospital, Helse Stavanger HF, Aarhus University Hospital, University Hospital, Bonn

CML, Relapsed

02/23

02/24

CLL-Frail, NCT04883749: Efficacy of Acalabrutinib in Very Old or Frail Patients with Treatment-naïve or Relapsed/Refractory CLL

Active, not recruiting

Europe

Acalabrutinib, Calquence, ACP-196

German CLL Study Group

Chronic Lymphoid Leukemia

05/25

DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting

168

Europe, RoW

MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab

Miltenyi Biomedicine GmbH, ICON plc

Diffuse Large B-cell Lymphoma

12/24

07/29

PALINDROM, NCT06172894: PBMC-based Leukocyte Immunotherapy

Recruiting

Europe

APN401

invIOs GmbH

Advanced Solid Tumor

03/24

NCT06250465: AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry

Recruiting

N/A

500

Europe

Arbeitsgemeinschaft medikamentoese Tumortherapie

Chronic Lymphocytic Leukemia

12/27

InflamGen, NCT04313231: Sterile Inflammation and Molecular Aberrations in MDS

Recruiting

N/A

130

Europe

Next Generation Sequencing, Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction, flow cytometry, Metagenomics of stool samples, Clinical/demographic data, Elicitation of the HRQoL

Medical University Innsbruck, University Hospital, Bonn, Universitätsklinikum Leipzig

Myelodysplastic Syndromes

01/23

PRO-RED, NCT05582902: Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients

Recruiting

N/A

Europe

University of Leipzig, Deutsche Krebshilfe e.V., Bonn (Germany)

MDS, MDS/MPN

03/25

Kiechl, Stefan

NCT04205006: Stroke Card Long-term Follow-Up

Enrolling by invitation

N/A

1000

Europe

Medical University Innsbruck, VASCage GmbH, Tirol Kiniken GmbH, Barmherzige Brüder Vienna

Ischemic Stroke, TIA

11/22

C-REGS2, NCT03480698: Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness

Active, not recruiting

N/A

1851

Europe

Cerebrolysin

Ever Neuro Pharma GmbH, IDV Data analysis and study planning Dr. Rahlfs

Acute Ischemic Stroke

04/24

10/24

NCT04582825: Stroke-Card Registry

Recruiting

N/A

5000

Europe

N/A - Observational Study

VASCage GmbH, Medical University Innsbruck, St John of God Hospital, Vienna

Ischemic Stroke, Transient Ischemic Attack

07/27

Egle, Daniel

POLAR, NCT03820830 / 2018-003553-19: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Recruiting

400

Europe

Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy

ETOP IBCSG Partners Foundation, Pfizer

Breast Cancer Recurrent

01/25

11/27

HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer

Active, not recruiting

654

Europe, Canada, Japan, US, RoW

Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo

Seagen Inc., Merck Sharp & Dohme LLC

HER2 Positive Breast Cancer

05/25

10/27

ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer

Active, not recruiting

Europe, Canada, Japan, US, RoW

Niraparib, Placebo

GlaxoSmithKline

Neoplasms, Breast

06/24

12/25

SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting

1332

Europe

Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy

German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER

HER2-negative Breast Cancer, Triple Negative Breast Cancer

03/27

03/29

TUXEDO-3, NCT05865990: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease

Active, not recruiting

Europe

Patritumab deruxtecan, HER3-DXd

MedSIR, Daiichi Sankyo

Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult

12/25

10/26

NCT03870620: Metastatic Breast Cancer in Austria

Recruiting

N/A

3000

Europe

Arbeitsgemeinschaft medikamentoese Tumortherapie, Hoffmann-La Roche, Daiichi Sankyo, Pfizer, Novartis, Caris Life Science, AstraZeneca, Seagen Inc., Eli Lilly and Company

Breast Cancer, Breast Carcinoma, Breast Tumor

06/25

TAXIS, NCT03513614: Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer

Recruiting

N/A

1500

Europe, Canada, US, RoW

Tailored axillary surgery - both Arms, Radiotherapy - Arm A, Radiotherapy - Arm B

University Hospital, Basel, Switzerland, ETOP IBCSG Partners Foundation, Austrian Breast Cancer Study Group

Node-positive Breast Cancer

12/29

12/36

Meersch

KDIGO-Bundle, NCT06472999: Nephroprotective Measures in Critically Ill Patients With Moderate/Severe Acute Kidney Injury

Recruiting

N/A

257

Europe

Nephroprotective measures

Universität Münster

Acute Kidney Injury

03/25

09/25

RIPC-ICU, NCT05830669: Remote Ischemic Preconditioning in Septic Patients

Recruiting

N/A

Europe

Remote ischemic preconditioning (RIPC), Sham RIPC

Universität Münster

Critically Ill, Acute Kidney Injury, Sepsis

10/25

01/26



	Diseases Companies Products Productz Mechanisms of Action Sites